Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...

Credit: Justin Paget via Getty Images. Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder ...

Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent ...

The label expansion is based on results from a trial that showed Spravato provided improvements over placebo in all 10 of the categories in the Montgomery-Asberg Depression Rating Scale (MADRS).

John­son & John­son’s Spra­va­to nasal spray re­ceived a la­bel ex­pan­sion on Tues­day, now ap­proved as a stand­alone treat­ment for ma­jor de­pres­sive dis­or­der in adults ...

Spravato is the only drug derived from ketamine that is FDA-approved to treat a psychiatric condition. Some health clinics offer ketamine off-label to treat mental health conditions, including ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Downsides of Spravato: Spravato’s warning label cautions about the risk of sedation and dissociation, respiratory depression, suicidal thoughts, and abuse or misuse of the drug, among other ...